DECISION-Project’s Post

🔈 BIG NEWS! DECISION has enrolled the first patient at Hôpital Beaujon, Clichy, France in the COMBAT Trial, a multicenter, randomized, open-label, Phase II clinical trial. This trial is a crucial component of the DECISION project, which aims to transform the treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF), investigating albumin and enoxaparin, a potential combinatorial therapy for decompensated cirrhosis. Read more in our press release: https://lnkd.in/dcsrwc54 Pierre-Emmanuel Rautou Greater Paris University Hospitals - AP-HP CARACENI Paolo Alma Mater Studiorum – Università di Bologna European Foundation for the Study of Chronic Liver Failure (EF CLIF) EASL | The Home of Hepatology #COMBATtrial #hepatology #cirrhosis #decompensation #ACLF #liver #Albumin #Enoxaparin #ClinicalTrial #PhaseIItrial #SciComm 

New year, new updates! 🎉 Today we announced #TargetRWE's novel #PrecisionMedicine Platform to undertake growing unmet medical needs in #LiverDisease, #Gastroenterology, and Immune-mediated Inflammatory Conditions. Learn about our 150,000+ biospecimen samples 👉 https://prn.to/4aHlmuF #PrecisionMedicine #RealWorldEvidence #RWE #RealWorldData #ClinicalResearch #DataAnalytics #GenomicResearch #PredictiveAnalytics #DiseaseProgression #PredictiveModeling Derek Evans

🌟 Exciting news from Annals of Hepatology! 🌟 📚 Our latest online publication, "Pathophysiology of Ascites: The Importance of the Intestine. A Surgical Contribution to the Understanding of a Medical Problem" by Gabriel Gondolesi, is now available! 🔍 Dive into this groundbreaking article where the pathophysiology of ascites formation is redefined. Discover how the intestine emerges as a game changer in understanding ascites production. 👩⚕️ Join us in exploring this innovative perspective on ascites and its implications for hepatology. Read the full (free) article here: https://lnkd.in/gWn_b3Rb #Ascites #Hepatology #MedicalResearch #InnovativeInsights #GameChanger 📝💡🔬

🌟New Study Reveals Key Determinant in Liver Disease! 🌍Non-alcoholic fatty liver disease (NAFLD) affects a third of the global population, leading to #LiverFibrosis, which significantly impacts disease severity and mortality. A recent study has now identified a crucial factor contributing to this condition. Researchers from Novartis (Novartis Biomedical Research, Basel) have used #CRISPR and #SpatialTranscriptomics technologies on primary human hepatic stellate cells to pinpoint ZNF469 as a key regulator of collagen expression, crucial for #LiverFibrosis in #NAFLD. This discovery was made through a comprehensive analysis involving transcriptional profiling of 108 human liver biopsies, covering the entire spectrum of #NAFLD. The #preprint study highlights how #ZNF469 directly interacts with genes and regulatory elements to control collagen levels and matrix homeostasis, marking it as a critical target for potential therapies. 💡 This breakthrough provides hope for better understanding and treating NAFLD-associated liver fibrosis, potentially saving millions of lives. 📖 Read the pre-print: https://hubs.ly/Q02vkkWS0 #Vizgen #MERSCOPE #LiverDisease

I did some cool science with some cool people! Check out this new study, where we examine the relationship between NASH, cellular senescence and mitochondrial bioenergetics, and the effects of both a short term and long term dietary intervention 🥦

Recently, I had the privilege of meeting a woman who spent decades awaiting a diagnosis for metabolic dysfunction-associated steatohepatitis (MASH), a chronic liver disease. This is not just her story. More than 115 million people around the world are living with MASH. Why should we pay attention to this? Due to progressive liver damage that can develop silently, MASH can often go undiagnosed for years. MASH is projected to become the leading cause of liver transplantation by 2030. Each delayed diagnosis is a missed opportunity for early intervention and improved patient outcomes. This underscores the urgent need for innovation in MASH. It is through such advancements that we could transform patient stories from journeys of uncertainty to narratives of hope and healing. Let's continue to push the boundaries of what's possible in healthcare, for the sake of patients worldwide. Today’s announcement of potential best-in-class data is pivotal in our mission to improve the lives of people living with MASH and liver fibrosis. I’m proud of the team for achieving this critical Phase II milestone! #EASLCongress #liverdisease #NEWS

📢 Exciting News in the Field of Gastroenterology! 🌟 SS Pharma is thrilled to share that the University of Birmingham is conducting a groundbreaking clinical trial named FARGO. This trial aims to explore whether faecal microbiota transplantation can effectively correct gut microbiome imbalances in patients with primary sclerosing cholangitis (PSC). Primary sclerosing cholangitis is a chronic liver disease that significantly impacts patients' quality of life. By addressing gut microbiome imbalances, the FARGO trial holds the potential to offer new hope and improved outcomes for PSC patients. We eagerly anticipate the results and the positive impact this trial could have on the PSC community. Stay tuned for updates! #ClinicalTrials #PSC #GutHealth #Microbiome #MedicalResearch #SSPharma #HealthcareInnovation

Finally online our new manuscript concerning the role of Nrf2 in driving metabolic reprogramming in normal hepatocytes published in “Hepatology”.

Interesting news in the world of liver research! Chinese researchers introduce a breakthrough noninvasive diagnostic tool for detecting non-alcoholic steatohepatitis (NASH), a severe form of fatty liver disease. Using sequential ultrasound molecular imaging (USMI) targeting specific markers, the method visualizes hepatic steatosis and inflammation with high diagnostic accuracy, presenting significant advancements in NASH detection. This innovation has the potential to enhance clinical decision-making and contribute to drug development for NASH treatment. Read more about it below! #LiverHealth #NASH #MedicalInnovation https://lnkd.in/gvwRcgxj

Don't overlook the chance to get your research published in the Global Journal of Gastroenterology & Hepatology Research. Please submit your manuscripts. To know more, visit here: https://lnkd.in/dqiVVkeZ WhatsApp Us: +447723493307 #GICancerResearch #GIcancer #GastroCancer #ColonCancer #RectalCancer #EsophagealCancer #StomachCancer #LiverCancer #PancreaticCancer #EsophagealDisease #GastricDisease #EsophagealHealth #GastricHealth #EsophagealDisorders